Eris Lifesciences Ltd (IN:ERIS)
:ERIS
Want to see IN:ERIS full AI Analyst Report?
Top Page
Eris Lifesciences Ltd
(ERIS)
Select Model
Select Model
Rating:60Neutral
Price Target:
₹1,408.00
▼(-8.02% Downside)
Action:Downgraded
Date:05/24/26
The score is primarily supported by strong operating profitability and improved leverage, but it is held back by sharply weaker FY2026 cash generation and poor cash conversion. Technically, the stock remains below key moving averages with only neutral momentum, while valuation is acceptable but not compelling given the P/E and low dividend yield.
Positive Factors
Strong operating margins
Consistently high FY2026 margins indicate durable pricing power in branded formulations and structural profitability in chronic therapies. Such margins create a buffer against cost shocks, support reinvestment in sales/brands, and underpin long-term return generation even if revenue growth moderates.
Negative Factors
Weak free cash flow & cash conversion
A sharp drop in operating cash flow and FCF versus earnings materially weakens cash conversion, raising earnings-quality concerns. Poor cash conversion limits capacity to fund capex, pay dividends or reduce debt without relying on external financing, increasing structural liquidity risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong operating margins
Consistently high FY2026 margins indicate durable pricing power in branded formulations and structural profitability in chronic therapies. Such margins create a buffer against cost shocks, support reinvestment in sales/brands, and underpin long-term return generation even if revenue growth moderates.
Read all positive factors
Eris Lifesciences Ltd (ERIS) vs. iShares MSCI India ETF (INDA)
Market Cap
₹198.23B
Dividend Yield0.47%
Average Volume (3M)2.07K
Price to Earnings (P/E)31.6
Beta (1Y)0.59
Revenue Growth8.15%
EPS Growth75.47%
CountryIN
Employees3,620
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)30.53
Shares Outstanding138,567,260
10 Day Avg. Volume1,915
30 Day Avg. Volume2,071
Financial Highlights & Ratios
PEG Ratio0.38
Price to Book (P/B)4.54
Price to Sales (P/S)5.67
P/FCF Ratio354.08
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)50.52
Revenue Forecast (FY)₹36.28B
Eris Lifesciences Ltd Business Overview & Revenue Model
Company Description
Eris Lifesciences Limited is an Indian pharmaceutical company engaged in the manufacturing, marketing, and distribution of medicinal products throughout the country. The company provides a comprehensive range of branded formulations, catering to a...
How the Company Makes Money
Eris Lifesciences makes money primarily by selling branded pharmaceutical formulations in India. Its core revenue stream is domestic prescription-drug sales generated through its field force promoting brands to doctors, with medicines subsequently...
Eris Lifesciences Ltd Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
71
Positive
Cash Flow
45
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 29.86B | 31.29B | 28.79B | 19.91B | 16.62B | 13.26B |
| Gross Profit | 22.36B | 14.98B | 21.49B | 16.04B | 13.05B | 10.65B |
| EBITDA | 10.86B | 11.11B | 10.36B | 6.99B | 5.48B | 5.11B |
| Net Income | 4.15B | 6.20B | 3.52B | 3.92B | 3.82B | 4.06B |
Balance Sheet | ||||||
| Total Assets | 71.60B | 73.66B | 70.33B | 70.49B | 36.67B | 22.72B |
| Cash, Cash Equivalents and Short-Term Investments | 839.20M | 763.80M | 2.28B | 13.39B | 892.43M | 2.12B |
| Total Debt | 23.89B | 23.59B | 24.78B | 27.81B | 8.77B | 844.07M |
| Total Liabilities | 36.56B | 34.70B | 37.61B | 38.27B | 14.47B | 3.64B |
| Stockholders Equity | 30.91B | 39.03B | 28.54B | 25.86B | 21.96B | 19.08B |
Cash Flow | ||||||
| Free Cash Flow | 1.22B | 500.70M | 9.10B | 3.57B | -5.50B | 2.57B |
| Operating Cash Flow | 2.39B | 3.47B | 10.65B | 4.86B | 2.92B | 3.78B |
| Investing Cash Flow | -1.39B | -3.72B | -799.70M | -18.55B | -9.82B | -3.20B |
| Financing Cash Flow | -2.43B | -1.20B | -8.81B | 13.80B | 6.88B | -446.99M |
Eris Lifesciences Ltd Technical Analysis
Positive
1530.85
Price Trends
1369.75
Positive
1362.00
Positive
1479.54
Negative
Market Momentum
11.40
Negative
59.76
Neutral
79.19
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ERIS, the sentiment is Positive. The current price of 1530.85 is above the 20-day moving average (MA) of 1374.85, above the 50-day MA of 1369.75, and above the 200-day MA of 1479.54, indicating a neutral trend. The MACD of 11.40 indicates Negative momentum. The RSI at 59.76 is Neutral, neither overbought nor oversold. The STOCH value of 79.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:ERIS.
Eris Lifesciences Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | ₹363.07B | 35.31 | ― | 1.07% | 14.50% | 47.08% | |
69 Neutral | ₹384.02B | 37.06 | ― | 2.16% | 1.93% | 11.69% | |
66 Neutral | ₹332.31B | 35.95 | ― | 0.21% | 16.56% | 34.08% | |
60 Neutral | ₹607.93B | 44.64 | ― | 0.24% | 27.48% | 30.05% | |
60 Neutral | ₹198.23B | 31.57 | ― | 0.47% | 8.15% | 75.47% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:ERIS
Eris Lifesciences Ltd
1,430.55
-184.88
-11.44%
IN:EMCURE
Emcure Pharmaceuticals Limited
1,752.15
442.51
33.79%
IN:GLAND
Gland Pharma Ltd.
2,200.95
495.19
29.03%
IN:GLAXO
GlaxoSmithKline Pharmaceuticals Limited
2,266.85
-858.95
-27.48%
IN:GLENMARK
Glenmark Pharmaceuticals Limited
2,154.25
521.31
31.92%
IN:SANOFICONR
Sanofi Consumer Healthcare India Limited
4,947.90
-127.30
-2.51%
Eris Lifesciences Ltd Corporate Events
Eris Lifesciences Faces Procedural GMP Observations After HALMED Audit of Swiss Parenterals Units
Apr 20, 2026
Eris Lifesciences has disclosed that Croatian regulator HALMED inspected Swiss Parenterals’ injectable manufacturing Units 1 and 2 in Ahmedabad in March 2026 and has now issued a list of non-compliance observations. The issues, which are des...
Eris Lifesciences Confirms Regulatory Compliance on Dematerialised Shares for Q4 FY26
Apr 10, 2026
Eris Lifesciences Ltd has submitted a confirmation certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026, to both BSE and NSE. The certificate, issued by its registrar...
Eris Lifesciences inducts veteran banker Vineet Varma as independent director
Mar 14, 2026
Eris Lifesciences has appointed veteran banker Vineet Varma as an additional non-executive independent director for a five-year term starting 14 March 2026, following board approval based on the nomination and remuneration committee’s recomm...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.